Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer

IMPORTANCE: Biologic therapy (BT) (eg, bevacizumab or cetuximab) is increasingly used to treat metastatic colorectal cancer (mCRC). Recent investigations have suggested that right- or left-sided primary tumor origin affects survival and response to BT. OBJECTIVE: To evaluate the association of tumor...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Surg
Autori principali: Aljehani, Mayada A., Morgan, John W., Guthrie, Laurel A., Jabo, Brice, Ramadan, Majed, Bahjri, Khaled, Lum, Sharon S., Selleck, Matthew, Reeves, Mark E., Garberoglio, Carlos, Senthil, Maheswari
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2017
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833618/
https://ncbi.nlm.nih.gov/pubmed/28975237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamasurg.2017.3466
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi